Effects of bisphosphonates on isolated Rat osteoclasts as examined by reflected light microscopy
The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.
Abstract
The bisphosphonates 4-amino-1-hydroxybutylidene-1, 1-bisphosphonic acid (ABP), 3-amino-1, 1-hydroxypropane-1, 1-diphosphonic acid (APD), and 1-hyroxyethane-1, 1-diphosphonic acid (EHDP) were compared for their ability to inhibit the osteoclastic resorption of bone in culture. This was achieved by measuring the effect of bisphosphonate concentration on the number of resorption pits formed and the total area of resorption. During this analysis, a new application of reflected polarized light microscopy was developed that has advantages over other microscopy techniques, including scanning electron microscopy (SEM), as applied to the analysis of resorbed bone surfaces. Based on area analysis, the bisphosphonates were effective for the range 10−7–10−8 M, with ABP about two to five times more effective than EHDP or APD. Similar data were obtained by counting the number of resorption pits but with EC50 10 times higher. At lower concentrations (10−9 M), bisphosphonates may enhance the formation of resorption pits. APD was found to be more toxic (10 times) than ABP or EHDP to osteoclasts and mononuclear cells, but toxic concentrations were at least 102 times higher than the resorption EC50. These data plus immunofluorescence, SEM, and transient incubation experiments show that it is the bisphosphonate-bone complex that directly inhibits the excavation of resorption pits by mature osteoclasts. The mechanism of action does not appear to require inhibition of osteoclast differentiation or toxic elimination of osteoclasts. Bisphosphonates, however, subtly affect the cytoskeleton of osteoclasts
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bisphosphonates do not appear to suppress osteoclastogenesis (129, 140, 141)”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [129]
In the citing paper
“In contrast, bisphosphonates have a different mechanism of action that can be associated with normal or even increased osteoclast numbers despite clear antiresorptive effects (129 -138).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [129]
Citations
Cites
Izzard, C. S., & Lochner, L. R. (1976) · Journal of Cell Science · doi:10.1242/jcs.21.1.129 · Cited by 705
Seaweeds and ulcerative colitis in laboratory animals.
Marcus, R., & Watt, J. (1969) · The Lancet · doi:10.1016/s0140-6736(69)90187-1 · Cited by 427
Resorption of bone by isolated rabbit osteoclasts
Chambers, T. J., Revell, P. A., Fuller, K., & Athanasou, N. A. (1984) · Journal of Cell Science · doi:10.1242/jcs.66.1.383 · Cited by 413
Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix.
Boonekamp, P. M., van der Wee-Pals, L. J. A., LENNEP, M. V., Cw, T., & Bijvoet, O. L. (1986) · PubMed · Cited by 345
Inoué, S. (1986) · Springer eBooks · doi:10.1007/978-1-4757-6925-8 · Cited by 342
Schenk, R., Eggli, P., Fleisch, H., & Rosini, S. (1986) · Calcified Tissue International · doi:10.1007/bf02555748 · Cited by 315
Structure-activity relationships of various bisphosphonates
Shinoda, H., Adamek, G., Felix, R., Fleisch, H., Schenk, R., & Hagan, P. (1983) · Calcified Tissue International · doi:10.1007/bf02405012 · Cited by 306
TREATMENT OF PAGET'S DISEASE WITH (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (A.P.D.)
Frijlink, W. B., Bijvoet, O. M., Te Velde, J., & Heynen, G. (1979) · The Lancet · doi:10.1016/s0140-6736(79)91318-7 · Cited by 258
Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases.
Elomaa, I., Blomqvist, C., Gröhn, P., Porkka, L., Kairento, A.-L., Selander, K., Lamberg-Allardt, C., & Holmström, T. (1983) · The Lancet · doi:10.1016/s0140-6736(83)92755-1 · Cited by 209
Quantitative reflection contrast microscopy of living cells.
Bereiter-Hahn, J., Fox, C. H., & Thorell, B. (1979) · The Journal of cell biology · doi:10.1083/jcb.82.3.767 · Cited by 195
Cited by
Marx, R. E. (2003) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/s0278-2391(03)00720-1 · Cited by 3,036
Bisphosphonates: The first 40years
Russell, R. G. G. (2011) · Bone · doi:10.1016/j.bone.2011.04.022 · Cited by 1,124
“This is much higher than the concentrations of bisphosphonates required to affect osteoclast morphology and cause osteoclast apoptosis in vitro [130].”
BackgroundBisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
Hughes, D. E., Wright, K. R., Uy, H. L., Sasaki, A., Yoneda, T., Roodman, D. G., Mundy, G. R., & Dr. Boyce, B. F. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650101008 · Cited by 1,040
Bisphosphonates: Mechanisms of Action
Fleisch, H. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0325 · Cited by 1,019
Sato, M., Grasser, W., Endo, N., Akins, R., Simmons, H., Thompson, D. D., Golub, E., & Rodan, G. A. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115539 · Cited by 1,004
“5 mM(data not shown), the EC50 for osteoclast 24-h cytotoxicity (42).”
BackgroundMethodSelf-citationCellular and molecular mechanisms of action of bisphosphonates
Rogers, M. J., Gordon, S., Benford, H. L., Coxon, F. P., Luckman, S. P., Monkkonen, J., & Frith, J. C. (2000) · Cancer · doi:10.1002/1097-0142(20000615)88:12+<2961::aid-cncr12>3.0.co;2-l · Cited by 977
Bisphosphonates: mechanisms of action.
Rodan, G. A., & Fleisch, H. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118722 · Cited by 921
“Changes in morphology, but no osteoclast toxicity, were apparent at the light or EM level in bone sections from animals treated with alendronate (34, 36, 39).”
BackgroundBisphosphonates: from the laboratory to the clinic and back again
Russell, R. G. G., & Rogers, M. J. (1999) · Bone · doi:10.1016/s8756-3282(99)00116-7 · Cited by 840
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Fleisch, H. (1991) · Drugs · doi:10.2165/00003495-199142060-00003 · Cited by 581
Molecular Mechanisms of Action of Bisphosphonates: Current Status
Roelofs, A. J., Thompson, K., Gordon, S., & Rogers, M. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0843 · Cited by 568
Abu-Amer, Y., Darwech, I., & Clohisy, J. C. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2170 · Cited by 534
“Animal models have been used to study the efficacy of an oral bisphosphonate in inhibiting bone resorption mediated by wear debris [26,66,67].”
Biochemical and molecular mechanisms of action of bisphosphonates
Rogers, M. J., Crockett, J. C., Coxon, F. P., & Mönkkönen, J. (2011) · Bone · doi:10.1016/j.bone.2010.11.008 · Cited by 530
“Furthermore, inhibition of bone resorption by N-BPs is not always associated with signs of cell toxicity or a decrease in osteoclast number except at high concentrations or doses [42,43].”
BackgroundChavassieux, P. M., Arlot, M. E., Reda, C., Wei, L., Yates, A. J., & Meunier, P. J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119668 · Cited by 523
Bisphosphonates: Mode of Action and Pharmacology
Russell, R. G. G. (2007) · Pediatrics · doi:10.1542/peds.2006-2023h · Cited by 503
Bisphosphonates act on rat bone resorption through the mediation of osteoblasts.
Sahni, M., Guenther, H. L., Fleisch, H., Collin, P., & Martin, T. J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116422 · Cited by 412
Bisphosphonates: From Bench to Bedside
RUSSELL, R. G. G. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1346.041 · Cited by 410
The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats
Seedor, J. G., Quartuccio, H. A., & Thompson, D. D. (1991) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650060405 · Cited by 407
Balena, R., Toolan, B. C., Shea, M., Markatos, A., Myers, E. R., Lee, S. C., Opas, E. E., Seedor, J. G., Klein, H., & Frankenfield, D. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116872 · Cited by 396
Osteoblast proliferation and maturation by bisphosphonates
Im, G.-I., Qureshi, S. A., Kenney, J., Rubash, H. E., & Shanbhag, A. S. (2004) · Biomaterials · doi:10.1016/j.biomaterials.2003.11.024 · Cited by 393
Bisphosphonates: An Update on Mechanisms of Action and How These Relate to Clinical Efficacy
RUSSELL, R. G. G., XIA, Z., DUNFORD, J. E., OPPERMANN, U., KWAASI, A., HULLEY, P. A., KAVANAGH, K. L., TRIFFITT, J. T., LUNDY, M. W., PHIPPS, R. J., et al. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1402.089 · Cited by 391
Management of Acute Hypercalcemia
Wood, A. J. J., & Bilezikian, J. P. (1992) · New England Journal of Medicine · doi:10.1056/nejm199204303261806 · Cited by 315
Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro.
van der Pluijm, G., Vloedgraven, H., van Beek, E., van der Wee-Pals, L., Löwik, C., & Papapoulos, S. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118841 · Cited by 305
“This well established in vitro model is mainly used to study the resorptive capacity of adherent osteoclasts (29, 37, 38).”
BackgroundBisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption
Vitte, C. (1996) · Endocrinology · doi:10.1210/en.137.6.2324 · Cited by 299
Rogers, M. J., Watts, D. J., & Russell, R. G. G. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971015)80:8+<1652::aid-cncr15>3.0.co;2-z · Cited by 285
The pharmacology of bisphosphonates and new insights into their mechanisms of action
Russell, R. G. G., Rogers, M. J., Frith, J. C., Luckman, S. P., Coxon, F. P., Benford, H. L., Croucher, P. I., Shipman, C., & Fleisch, H. A. (1999) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650140212 · Cited by 279
Osteonecrosis of the Jaw in a Patient on Denosumab
Aghaloo, T. L., Felsenfeld, A. L., & Tetradis, S. (2010) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2009.10.010 · Cited by 275
Luckman, S. P., Coxon, F. P., Ebetino, F. H., Russell, R. G. G., & Rogers, M. J. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.11.1668 · Cited by 272
Studies of the oral bioavailability of alendronate*
Gertz, B. J., Holland, S. D., Kline, W. F., Matuszewski, B. K., Freeman, A., Quan, H., Lasseter, K. C., Mucklow, J. C., & Porras, A. G. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90245-7 · Cited by 262
Comparison of the distribution of 3H-alendronate and 3H-Etidronate in rat and mouse bones
Masarachia, P., Weinreb, M., Balena, R., & Rodan, G. A. (1996) · Bone · doi:10.1016/8756-3282(96)00182-2 · Cited by 248
Maksymowych, W. P., Jhangri, G. S., Fitzgerald, A. A., LECLERCQ, S. A., Chiu, P., Yan, A., Skeith, K. J., Aaron, S. L., Homik, J., Davis, P. J., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10139 · Cited by 244
Bisphosphonates: Pharmacology, Mechanisms of Action and Clinical Uses
Russell, R. G. G., Croucher, P. I., & Rogers, M. J. (1999) · Osteoporosis International · doi:10.1007/pl00004164 · Cited by 240
BM 21.0955, a potent new bisphosphonate to inhibit bone resorption.
Mühlbauer, R. C., Bauss, F., Schenk, R., Janner, M., Bosies, E., Strein, K., & Fleisch, H. (1991) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650060915 · Cited by 239
Molecular mechanisms of action of bisphosphonates
Rogers, M. J., Frith, J. C., Luckman, S. P., Coxon, F. P., Benford, H. L., M̈onkk̈onen, J., Auriola, S., Chilton, K. M., & Russell, R. G. G. (1999) · Bone · doi:10.1016/s8756-3282(99)00070-8 · Cited by 237
Echistatin is a potent inhibitor of bone resorption in culture.
Sato, M., Sardana, M. K., Grasser, W. A., Garsky, V. M., Murray, J. M., & Gould, R. J. (1990) · The Journal of cell biology · doi:10.1083/jcb.111.4.1713 · Cited by 197
Self-citationBisphosphonate Mechanism of Action
Rodan, G., & Reszka, A. (2002) · Current Molecular Medicine · doi:10.2174/1566524023362104 · Cited by 195
Dr. Rogers, M. J., Chilton, K. M., Coxon, F. P., Lawry, J., Smith, M. O., Suri, S., & Russel, R. G. G. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650111015 · Cited by 194
Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates
van Beek, E. R., Cohen, L. H., Leroy, I. M., Ebetino, F. H., Löwik, C. W. G. M., & Papapoulos, S. E. (2003) · Bone · doi:10.1016/j.bone.2003.07.007 · Cited by 184
“Suppression of this enzyme in osteoclasts by NBPS causes inhibition of the synthesis of FPP and GGPP and thereby of the prenylation of small GTP-binding proteins like CdC42, rho, and rab and disruption of the organization of the cytoskeleton of these cells [10–14].”
BackgroundBisphosphonate mechanism of action
Reszka, A. A., & Rodan, G. A. (2003) · Current Rheumatology Reports · doi:10.1007/s11926-003-0085-6 · Cited by 179
“The changes are numerous [ 48 ] and include alterations in the cytoskeleton, including actin and vinculin, as well as disruption of the ruffled border [6,69– 71].”
BackgroundEffect of bisphosphonate (Incadronate) on fracture healing of long bones in rats.
Li, J., Mori, S., Kaji, Y., Mashiba, T., Kawanishi, J., & Norimatsu, H. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.6.969 · Cited by 178
“Bisphosphonates inhibit osteoclast activity((31,32)) and their continuous long-term use further inhibits osteoclast differentiation.”
BackgroundPan, B., Farrugia, A. N., To, L. B., Findlay, D. M., Green, J., Lynch, K., & Zannettino, A. C. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2004.19.1.147 · Cited by 157
The antineoplastic role of bisphosphonates: from basic research to clinical evidence
Santini, D., Vespasiani Gentilucci, U., Vincenzi, B., Picardi, A., Vasaturo, F., La Cesa, A., Onori, N., Scarpa, S., & Tonini, G. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg401 · Cited by 171
“After cellular uptake, bisphosphonate-treated osteoclasts show important changes in morphology, both in vitro [23, 25] and in vivo [26–28].”
BackgroundRogers, M. J. (2004) · Calcified Tissue International · doi:10.1007/s00223-004-0024-1 · Cited by 164
“Furthermore, inhibition of bone resorption by N-BPs is not always associated with signs of cell toxicity or a decrease in osteoclast number except at high concentrations [73, 75].”
BackgroundBisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures
Nishikawa, M., Akatsu, T., Katayama, Y., Yasutomo, Y., Kado, S., Kugai, N., Yamamoto, M., & Nagata, N. (1996) · Bone · doi:10.1016/8756-3282(95)00426-2 · Cited by 161
Clinical pharmacology of alendronate sodium
Gertz, B. J., Holland, S. D., Kline, W. F., Matuszewski, B. K., & Porras, A. G. (1993) · Osteoporosis International · doi:10.1007/bf01623002 · Cited by 159
van Beek, E. R., Löwik, C. W. G. M., & Papapoulos, S. E. (2002) · Bone · doi:10.1016/s8756-3282(01)00655-x · Cited by 159
Azuma, Y., Sato, H., Oue, Y., OKABE, K., Ohta, T., Tsuchimoto, M., & Kiyoki, M. (1995) · Bone · doi:10.1016/8756-3282(94)00035-x · Cited by 157
Galvin, R. J. S., Gatlin, C. L., Horn, J. W., & Fuson, T. R. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1632 · Cited by 144
Greenfield, E. M., Shaw, S. M., Gornik, S. A., & Banks, M. A. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118157 · Cited by 134
Bisphosphonate-associated osteonecrosis of the jaws
Markiewicz, M. R., Margarone, J. E., Campbell, J. H., & AGUIRRE, A. (2005) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2005.0109 · Cited by 137
Bisphosphonates: an overview with special reference to alendronate
Vasikaran, S. D. (2001) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/0004563011901037 · Cited by 137
Pan, B.-Q., To, L. B., Farrugia, A. N., Findlay, D. M., Green, J., Gronthos, S., Evdokiou, A., Lynch, K., Atkins, G. J., & Zannettino, A. C. W. (2003) · Bone · doi:10.1016/j.bone.2003.08.013 · Cited by 128
“apoptosis of mature OC [1,4,15,25,32,35,38], recent studies show that these compounds also inhibit bone resorption indirectly by modulating the expression of osteoclastogenic factors synthesised by osteoblasts (OBs) [8,11,26,31,39].”
BackgroundEffect of alendronate on cultured normal human osteoblasts
García-Moreno, C., Serrano, S., Nacher, M., Farré, M., Díez‐Pérez, A., Mariñoso, M. L., Abelló, J. C., Mellibovsky, L., Nogués, X., Soleda, J. B., et al. (1998) · Bone · doi:10.1016/s8756-3282(97)00270-6 · Cited by 128
The effects of bisphosphonates on the resorption cycle of isolated osteoclasts
Selander, K. S., Lehenkari, P. P., & V��n�nen, H. K. (1994) · Calcified Tissue International · doi:10.1007/bf00299317 · Cited by 123
“peroxidase-conjugated WGA-lectins offers a fast, simple, and semiautomatic technique, which provides a practical alternative to the methods already in use for visualization and quantitation of resorption pits [16-22].”
BackgroundMethodHuman Osteoclast Formation and Activity In Vitro: Effects of Alendronate
Breuil, V., Cosman, F., Stein, L., Horbert, W., Nieves, J. W., Shen, V., Lindsay, R., & Dempster, D. W. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.11.1721 · Cited by 122
“The purpose of the present study was to characterize further the in vitro assay of human OC formation and to examine the effects of alendronate (ALN) on both recruitment and activity of human OCs.”
BackgroundInfluentialPlosker, G. L., & Goa, K. L. (1994) · Drugs · doi:10.2165/00003495-199447060-00007 · Cited by 119
Emerging Therapies for the Prevention or Treatment of Postmenopausal Osteoporosis
Sato, M., Grese, T. A., Dodge, J. A., Bryant, H. U., & Turner, C. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980344o · Cited by 107
Self-citationBisphosphonates: effects on osteoblast
Maruotti, N., Corrado, A., Neve, A., & Cantatore, F. P. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1216-7 · Cited by 112
Tenenbaum, H. C., Shelemay, A., Girard, B., Zohar, R., & Fritz, P. C. (2002) · Journal of Periodontology · doi:10.1902/jop.2002.73.7.813 · Cited by 112
Weinreb, M., Quartuccio, H. A., Seedor, J. G., Aufdemorte, T. B., Brunsvold, M. A., Chaves, E. S., Kornman, K. S., & Rodan, G. A. (1994) · Journal of Periodontal Research · doi:10.1111/j.1600-0765.1994.tb01088.x · Cited by 111
Synovial fluid macrophages are capable of osteoclast formation and resorption
Adamopoulos, I., Sabokbar, A., Wordsworth, B., Carr, A., Ferguson, D., & Athanasou, N. (2006) · The Journal of Pathology · doi:10.1002/path.1891 · Cited by 103
“The extent of lacunar resorption on the dentine slice was determined by point counting, as previously described [19,20].”
MethodBoyce, R. W., Paddock, C. L., Gleason, J. R., Sletsema, W. K., & Eriksen, E. F. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650100207 · Cited by 99
Neville-Webbe, H. L., & Coleman, R. E. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.041 · Cited by 105
The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboons
Thompson, D. D., Seedor, J. G., Quartuccio, H. A., Solomon, H. F., Fioravanti, C., Davidson, J. S., Klein, H. J., Jackson, R., Clair, J. S., Frankenfield, D., et al. (1992) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650070812 · Cited by 104
Li, J., Mori, S., Kaji, Y., Kawanishi, J., Akiyama, T., & Norimatsu, H. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.10.2042 · Cited by 95
“Besides their toxic effect on osteoclasts, (39) bisphosphonates can inhibit the function of osteoclasts through their effect on osteoclast precursors, (21) activity,((19,40)) and survival.”
BackgroundThe effect of alendronate sodium on spinal fusion: a rabbit model
Lehman, R. A., Kuklo, T. R., Freedman, B. A., Cowart, J. R., Mense, M. G., & Riew, K. D. (2004) · The Spine Journal · doi:10.1016/s1529-9430(03)00427-3 · Cited by 99
“Alendronate (4-amino-1-hydroxybutylidene-1, 1-bisphosphonate sodium) is a potent bisphosphonate that inhibits osteoclast-mediated bone resorption [7–9].”
BackgroundAlendronate: An Update of its Use in Osteoporosis
Sharpe, M., Noble, S., & Spencer, C. M. (2001) · Drugs · doi:10.2165/00003495-200161070-00010 · Cited by 97
“Inhibits osteoclast-mediated bone resorption[22,24-26]”
Kim, T.-W., Yoshida, Y., Yokoya, K., & Sasaki, T. (1999) · American Journal of Orthodontics and Dentofacial Orthopedics · doi:10.1016/s0889-5406(99)70290-8 · Cited by 97
A role for CD8+ T lymphocytes in osteoclast differentiation in vitro
John, V. (1996) · Endocrinology · doi:10.1210/en.137.6.2457 · Cited by 88
New resorption assay with mouse osteoclast-like multinucleated cells formed in vitro
Tamura, T., Takahashi, N., Akatsu, T., Sasaki, T., Udagawa, N., Tanaka, S., & Suda, T. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080808 · Cited by 96
Regulation of osteoclast differentiation by statins.
Wa, G., Ap, B., Petras, S. F., Hj, H., Devalaraja, R., Renkiewicz, R. R., Baragi, Dd, T., & Vm, P. (2003) · PubMed · Cited by 92
Nicotine Stimulates Osteoclast Resorption in a Porcine Marrow Cell Model
Henemyre, C. L., K. Scales, D., Hokett, S. D., Cuenin, M. F., Peacock, M. E., Parker, M. H., Brewer, P. D., & Chuang, A. H. (2003) · Journal of Periodontology · doi:10.1902/jop.2003.74.10.1440 · Cited by 82
New bisphosphonates in osteoporosis
Fleisch, H. A. (1993) · Osteoporosis International · doi:10.1007/bf01623222 · Cited by 91
“Indeed, the addition of bisphosphonates in vitro to osteoclasts exposed to mineralized tissue leads to an inhibition of their resorbing activity [44-46].”
BackgroundSharma, A., & Pradeep, A. R. (2011) · Journal of Periodontology · doi:10.1902/jop.2011.110206 · Cited by 89
Rationale for the use of alendronate in osteoporosis
Kanis, J. А., Gertz, B. J., Singer, F. R., & Ortolani, S. (1995) · Osteoporosis International · doi:10.1007/bf01623652 · Cited by 89
“This view is consistent with the ultrastructural changes at the ruffled border observed in rat osteoclasts after treatment with alendronate [ 29 ].”
BackgroundResultInfluentialJeal, W., Barradell, L. B., & McTavish, D. (1997) · Drugs · doi:10.2165/00003495-199753030-00006 · Cited by 87
Wimalawansa, S. J. (1994) · Cancer · doi:10.1002/1097-0142(19940415)73:8<2223::aid-cncr2820730831>3.0.co;2-c · Cited by 84
Alendronate Modulates Osteogenesis of Human Osteoblastic Cells In Vitro
Tsuchimoto, M., Azuma, Y., Higuchi, O., Sugimoto, I., Hiraia, N., Kiyoki, M., & Yamamoto, I. (1994) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.66.25 · Cited by 83
Evely, R. S., Bonomo, A., Schneider, H. G., Moseley, J. M., Gallagher, J. A., & Martin, T. (1991) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650060114 · Cited by 80
Kim, T., Ha, Y.-C., Kang, B.-J., Lee, Y., & Koo, K.-H. (2012) · Journal of Bone and Joint Surgery - British Volume · doi:10.1302/0301-620x.94b7.29079 · Cited by 79
Katsumi, H., Liu, S., Tanaka, Y., Hitomi, K., Hayashi, R., Hirai, Y., Kusamori, K., Quan, Y., Kamiyama, F., Sakane, T., et al. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23136 · Cited by 74
Kaynak, D., Meffert, R. M., Günhan, M., Günhan, Ö., & Özkaya, Ö. (2000) · Journal of Periodontology · doi:10.1902/jop.2000.71.5.790 · Cited by 74
Rogers, M. J., Watts, D. J., Russell, R. G. G., Ji, X., Xiong, X., Blackburn, G. M., Bayless, A. V., & Ebetino, F. H. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090710 · Cited by 73
New Bisphosphonates in the Treatment of Bone Diseases
Gatti, D., & Adámi, S. (1999) · Drugs & Aging · doi:10.2165/00002512-199915040-00004 · Cited by 72
Buduneli, E., Vardar‐Şengül, S., Buduneli, N., Atilla, G., Wahlgren, J., & Sorsa, T. A. (2007) · Journal of Periodontology · doi:10.1902/jop.2007.050451 · Cited by 64
Pradeep, A. R., Kumari, M., Rao, N. S., & Naik, S. B. (2012) · Journal of Periodontology · doi:10.1902/jop.2012.110729 · Cited by 64
Differentiation dependent expression of tensin and cortactin in chicken osteoclasts
Hiura, K., Lim, S., Little, S. P., Lin, S., & Sato, M. (1995) · Cell Motility and the Cytoskeleton · doi:10.1002/cm.970300405 · Cited by 64
Self-citationExpression of RANKL/OPG during bone remodeling in vivo
Tanaka, H., Mine, T., Ogasa, H., Taguchi, T., & Liang, C. T. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.07.001 · Cited by 62
Impact of Bisphosphonates on Survival for Patients With Duchenne Muscular Dystrophy
Gordon, K., Dooley, J. M., Sheppard, K. M., MacSween, J., & Esser, M. J. (2011) · PEDIATRICS · doi:10.1542/peds.2010-1666 · Cited by 62
Licata, A. A. (1997) · The American Journal of the Medical Sciences · doi:10.1097/00000441-199701000-00004 · Cited by 62
Inoue, R., Matsuki, N., Gao, J., Kanematsu, T., Abe, K., & Hirata, M. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706373 · Cited by 61
“Amino-BP also affect osteoclast function, including causing loss of the ruffled border, disruption of the actin cytoskeleton and induction of osteoclast apoptosis (Sato & Grasser, 1990; Fisher et al., 1999).”
BackgroundThe Influence of Alendronate on Spine Fusion in an Osteoporotic Animal Model
Nakao, S.-I., Minamide, A., Kawakami, M., Boden, S. D., & Yoshida, M. (2011) · Spine · doi:10.1097/brs.0b013e3181f49c47 · Cited by 61
BOYDE, A., & Jones, S. J. (1991) · Calcified Tissue International · doi:10.1007/bf02565123 · Cited by 61
Abildgaard, N., Rungby, J., Glerup, H., Brixen, K., Kassem, M. S., Brincker, H., Heickendorff, L., Eriksen, E. F., & Nielsen, J. (1998) · European Journal Of Haematology · doi:10.1111/j.1600-0609.1998.tb01073.x · Cited by 59
“elimination or by inducing apoptosis of these cells (34, 35).”
BackgroundDrugs in development: bisphosphonates and metalloproteinase inhibitors
Catterall, J. B., & Cawston, T. E. (2003) · Arthritis Research · doi:10.1186/ar604 · Cited by 58
“Cellular uptake of bisphosphonates leads to the loss of the ruffled border between the osteoclast and the bone surface [20,21], to disruption of the cytoskeleton [19,22] and to loss of function.”
BackgroundBisphosphonates in bone cement inhibit PMMA particle induced bone resorption
Sabokbar, A., Fujikawa, Y., Murray, D. W., & Athanasou, N. A. (1998) · Annals of the Rheumatic Diseases · doi:10.1136/ard.57.10.614 · Cited by 56
Saito, M., Shiraishi, A., Ito, M., Sakai, S., Hayakawa, N., Mihara, M., & Marumo, K. (2009) · Bone · doi:10.1016/j.bone.2009.12.008 · Cited by 55
“The results of previous studies indicated that bisphosphonates suppress bone resorption by inhibiting osteoclast activity [33] and that their continuous long-term use further inhibits osteoclast differentiation [34].”
ResultBisphosphonates-Anti-Inflammatory Properties
Maksymowych, W. P. (2002) · Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry · doi:10.2174/1568014024606539 · Cited by 55
Hoefert, S., Schmitz, I., Weichert, F., Gaspar, M., & Eufinger, H. (2014) · Clinical Oral Investigations · doi:10.1007/s00784-014-1273-7 · Cited by 53
Kusamori, K., Katsumi, H., Abe, M., Ueda, A., Sakai, R., Hayashi, R., Hirai, Y., Quan, Y., Kamiyama, F., Sakane, T., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.147 · Cited by 52
“Among the nitrogen-containing BPs, alendronate sodium (sodium-4-amino-1-hydroxybutylidene-1,1-bisphosphonate trihydrate) has been used as the first-choice drug for the treatment of hypercalcemia and osteoporosis in postmenopausal women.((13)) However, the oral bioavailability (BA) of alendronate is approximately 0.”
Method
Metadata
- Authors
- Sato, M., & Grasser, W.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Sato, Masahiko
- ORCID
- Sato, Masahiko
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 1990-01-01
- Volume
- 5
- Issue
- 1
- Pages
- 31-40
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W1974903174
- Cited by
- 264
- References
- 35
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 3 · 2022: 1 · 2021: 4 · 2020: 3 · 2019: 3 · 2018: 2 · 2017: 2 · 2016: 5 · 2015: 5 · 2014: 6 · 2013: 1 · 2012: 6
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Journal of Bone and Mineral Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Merck Sharp and Dohme
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Keywords
- bisphosphonates, osteoclasts, bone resorption, 1-hydroxyethane-1,1-diphosphonic acid, resorption pits, bisphosphonate toxicity, mechanism of action
- MeSH terms
- Pamidronate, Animals, Bone Resorption, Cattle, Cell Survival, Diphosphonates, Microscopy, Fluorescence, Microscopy, Phase-Contrast, Microscopy, Polarization, Osteoclasts, Rats, Inbred Strains, Etidronic Acid, Video Recording, Alendronate, Rats, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.